CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial

CYP2D6 and UGT2B7 Genotype and Risk of Recurrence in Tamoxifen-Treated Breast Cancer Patients

(2012) James M. Rae et al.   JNCI-Journal of the National Cancer Institute

Which patients benefit most from adjuvant aromatase inhibitors? Results using a composite measure of prognostic risk in the BIG 1-98 randomized trial

(2011) G. Viale et al.   ANNALS OF ONCOLOGY

Tamoxifen Metabolite Concentrations, CYP2D6 Genotype, and Breast Cancer Outcomes

(2011) L Madlensky et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Analyses Adjusting for Selective Crossover Show Improved Overall Survival With Adjuvant Letrozole Compared With Tamoxifen in the BIG 1-98 Study

(2011) Marco Colleoni et al.   JOURNAL OF CLINICAL ONCOLOGY

CYP2D6 Inhibition and Breast Cancer Recurrence in a Population-Based Study in Denmark

(2011) T. L. Lash et al.   JNCI-Journal of the National Cancer Institute

Pharmacogenetics of Endocrine Therapy for Breast Cancer

(2010) Michaela J. Higgins et al.   Annual Review of Medicine

Endoxifen, a New Cornerstone of Breast Cancer Therapy: Demonstration of Safety, Tolerability, and Systemic Bioavailability in Healthy Human Subjects

(2010) A Ahmad et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

High-efficiency genotype analysis from formalin-fixed, paraffin-embedded tumor tissues

(2010) M J Sikora et al.   PHARMACOGENOMICS JOURNAL

Association between CYP2D6 genotype and tamoxifen-induced hot flashes in a prospective cohort

(2009) N. Lynn Henry et al.   BREAST CANCER RESEARCH AND TREATMENT

The Tamoxifen Metabolite, Endoxifen, Is a Potent Antiestrogen that Targets Estrogen Receptor   for Degradation in Breast Cancer Cells

(2009) X. Wu et al.   CANCER RESEARCH

Pharmacogenomics of Tamoxifen Therapy

(2009) H. Brauch et al.   CLINICAL CHEMISTRY

Association Between CYP2D6 Polymorphisms and Outcomes Among Women With Early Stage Breast Cancer Treated With Tamoxifen

(2009) Werner Schroth   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Letrozole Therapy Alone or in Sequence with Tamoxifen in Women with Breast Cancer

(2009)   NEW ENGLAND JOURNAL OF MEDICINE

Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients

(2009) J M Rae et al.   PHARMACOGENOMICS JOURNAL

Pharmacogenomic Variation of CYP2D6 and the Choice of Optimal Adjuvant Endocrine Therapy for Postmenopausal Breast Cancer: A Modeling Analysis

(2008) R. S. Punglia et al.   JNCI-Journal of the National Cancer Institute

Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial

(2008) Jack Cuzick et al.   LANCET ONCOLOGY